<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Checkpoint-timing synergy and regimen optimization (CTSO) - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Theory Details for theory-26</h1>

        <div class="section">
            <h2>Theory (General Information)</h2>
            <div class="info-section">
                <p><strong>ID:</strong> theory-26</p>
                <p><strong>Name:</strong> Checkpoint-timing synergy and regimen optimization (CTSO)</p>
                <p><strong>Type:</strong> general</p>
                <p><strong>Theory Query:</strong> Build a theory of why neoadjuvant-plus-adjuvant immunotherapy improves melanoma outcomes compared to adjuvant-only immunotherapy, based on the following results.</p>
                <p><strong>Description:</strong> The magnitude of benefit from a neoadjuvant-inclusive strategy depends on the synergy between checkpoint targets engaged while tumor antigen is present. CTLA-4+PD-1 combinations maximize clonal breadth and intratumoral reinvigoration but increase toxicity, while PD-1+LAG-3 can yield high pathologic responses with lower preoperative toxicity. Targeted therapy–driven pCRs lack durable immune memory unless paired with immunotherapy.</p>
                <p><strong>Knowledge Cutoff Year:</strong> 2029</p>
                <p><strong>Knowledge Cutoff Month:</strong> 12</p>
                <p><strong>Base Model:</strong> openai/gpt-5</p>
            </div>
        </div>
        </div>

        <div class="section">
            <h2>Theory (Statement/Laws)</h2>

            <h3>Theory Statements/Laws</h3>
            <hr/>
            <h3>Statement 0: Law 0</h3>
            <p><strong>Statement:</strong> None</p>
            <p><strong>Domain/Scope:</strong> <span class="empty-note">Not specified.</span></p>
            <h4>Special Cases</h4>
            <h4>Supporting Evidence for this Law</h4>
<p class="empty-note">No evidence provided.</p>            <h4>Self-Evaluation of Law Novelty (produced by the generation model)</h4>
            <p><strong>Likely Classification:</strong> unknown</p>
        <p><strong>Explanation:</strong> No explanation provided.</p>
        <p><strong>References:</strong> <span class="empty-note">No references provided.</span>            <h4>External Evaluations of this Law</h4>
            <p><strong>Predictive Accuracy Evaluation:</strong> <span class="empty-note">Not available.</span></p>
            <p><strong>Novelty Evaluation:</strong> <span class="empty-note">Not available (available only for a randomly selected subset of 100 laws, due to cost).</span></p>
            <hr/>
            <h3>Statement 1: Law 1</h3>
            <p><strong>Statement:</strong> None</p>
            <p><strong>Domain/Scope:</strong> <span class="empty-note">Not specified.</span></p>
            <h4>Special Cases</h4>
            <h4>Supporting Evidence for this Law</h4>
<p class="empty-note">No evidence provided.</p>            <h4>Self-Evaluation of Law Novelty (produced by the generation model)</h4>
            <p><strong>Likely Classification:</strong> unknown</p>
        <p><strong>Explanation:</strong> No explanation provided.</p>
        <p><strong>References:</strong> <span class="empty-note">No references provided.</span>            <h4>External Evaluations of this Law</h4>
            <p><strong>Predictive Accuracy Evaluation:</strong> <span class="empty-note">Not available.</span></p>
            <p><strong>Novelty Evaluation:</strong> <span class="empty-note">Not available (available only for a randomly selected subset of 100 laws, due to cost).</span></p>
            <hr/>
            <h3>Statement 2: Law 2</h3>
            <p><strong>Statement:</strong> None</p>
            <p><strong>Domain/Scope:</strong> <span class="empty-note">Not specified.</span></p>
            <h4>Special Cases</h4>
            <h4>Supporting Evidence for this Law</h4>
<p class="empty-note">No evidence provided.</p>            <h4>Self-Evaluation of Law Novelty (produced by the generation model)</h4>
            <p><strong>Likely Classification:</strong> unknown</p>
        <p><strong>Explanation:</strong> No explanation provided.</p>
        <p><strong>References:</strong> <span class="empty-note">No references provided.</span>            <h4>External Evaluations of this Law</h4>
            <p><strong>Predictive Accuracy Evaluation:</strong> <span class="empty-note">Not available.</span></p>
            <p><strong>Novelty Evaluation:</strong> <span class="empty-note">Not available (available only for a randomly selected subset of 100 laws, due to cost).</span></p>
            <hr/>
        </div>
        <div class="section">
            <h2>Theory (Additional Details)</h2>
                        <h3>New Predictions (Likely outcome)</h3>
            <ol>
                <li>Neoadjuvant ipi 1 + nivo 3 ×2 will produce higher MPR and similar or lower grade ≥3 irAEs than ipi 3 + nivo 1 ×2 across centers, with superior patient-reported outcomes vs standard dosing.</li>
                <li>Neoadjuvant RELA+NIVO responders will show enrichment of TRM-IFNG signatures and a higher fraction of LAG-3+PD-1+ clonotypes at the invasive margin compared with PD-1 monotherapy.</li>
            </ol>
            <h3>New Predictions (Unknown outcome/high-entropy)</h3>
            <ol>
                <li>Adaptive perioperative sequencing (one cycle PD-1 → assess; if non-inflamed switch to PD-1+CTLA-4) will match dual upfront efficacy with lower toxicity.</li>
                <li>A PD-1 priming dose followed by short targeted-therapy window will improve MPR and 2-year RFS over targeted-only in BRAF-mutant disease; magnitude unknown.</li>
            </ol>
            <h3>Negative Experiments</h3>
            <ol>
                <li>If adjuvant-only PD-1 equals neoadjuvant ipi+nivo in EFS in a head-to-head trial with balanced follow-up, the timing–synergy claim would be undermined.</li>
                <li>If PD-1+LAG-3 neoadjuvant cohorts fail to show high MPR or reveal high neoadjuvant G3–4 irAEs across studies, the ‘lower-toxicity’ optimization claim would fail.</li>
            </ol>
            <h3>Unaccounted for Evidence</h3>
<ol>
    <li>Which biomarkers (IFN-γ signature vs TMB vs PD-L1) best triage patients to PD-1 monotherapy vs dual checkpoint in the neoadjuvant window remains unsettled. <a href="../results/extraction-result-18.html#e18.2" class="evidence-link">[e18.2]</a> <a href="../results/extraction-result-20.html#e20.0" class="evidence-link">[e20.0]</a> </li>
</ol>        </div>        <div style="height: 30px;"></div>
    </div>
</body>
</html>